Ingenix, a Warsaw-based AI and biology startup, has raised a €13 million seed extension led by Sofinnova Partners, with participation from Inovo VC and OTB VC.
Founded in 2023, the company is developing a Biological Reasoning Engine designed to support translational and clinical R&D decisions. Ingenix says the new funding will be used to scale development of the platform and expand work with pharma and biotech companies through its Qualified Access Program.
The company’s approach centers on what it calls Modality Fusion, an AI architecture intended to integrate models across different biological data types and scales. The investment adds to growing interest in tools aimed at applying AI more directly to drug discovery and development, particularly in areas where companies argue general-purpose models fall short.
Founded in 2023, the company is developing a Biological Reasoning Engine designed to support translational and clinical R&D decisions. Ingenix says the new funding will be used to scale development of the platform and expand work with pharma and biotech companies through its Qualified Access Program.
The company’s approach centers on what it calls Modality Fusion, an AI architecture intended to integrate models across different biological data types and scales. The investment adds to growing interest in tools aimed at applying AI more directly to drug discovery and development, particularly in areas where companies argue general-purpose models fall short.